J. Safra Asset Management’s Celldex Therapeutics CLDX Stock Holding History

J. Safra Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.62K	Hold	151	–	–	﹤0.01%	476
2026 Q1	$4.79K	Buy	151 +71	+89%	+$1.94K	﹤0.01%	478
2025 Q4	$2.17K	Buy	80 +40	+100%	+$1.05K	﹤0.01%	553
2025 Q3	$1.03K	Sell	40 -195	-83%	-$4.52K	﹤0.01%	453
2025 Q2	$4.78K	Sell	235 -95	-29%	-$1.85K	﹤0.01%	327
2025 Q1	$5.99K	Buy	330 +18	+6%	+$402	﹤0.01%	308
2024 Q4	$7.84K	Buy	312 +129	+70%	+$3.5K	﹤0.01%	298
2024 Q3	$6.08K	Buy	183 +158	+632%	+$6.02K	﹤0.01%	256
2024 Q2	$925	Buy	+25	New	+$943	﹤0.01%	254

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

J. Safra Asset Management's CLDX Position: Q2 2026 in Review

J. Safra Asset Management held its Celldex Therapeutics (CLDX) position steady in Q2 2026 at 151 shares worth $5.62K. The position accounts for ﹤0.01% of the portfolio, ranked #476.

J. Safra Asset Management first reported a position in CLDX in Q2 2024 and has held it in 9 quarters since. The position peaked at $7.84K in Q4 2024. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

J. Safra Asset Management held 151 shares of Celldex Therapeutics worth $5.62K as of Q2 2026.
J. Safra Asset Management left its Celldex Therapeutics share count unchanged in Q2 2026.
Celldex Therapeutics made up ﹤0.01% of J. Safra Asset Management's portfolio in Q2 2026, its #476 holding.
J. Safra Asset Management first reported a position in Celldex Therapeutics in Q2 2024 and has held it in 9 quarters since.
J. Safra Asset Management's Celldex Therapeutics position peaked at $7.84K in Q4 2024.
253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on J. Safra Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.